Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Eddingpharm Pays $2.7 Million Upfront for China Rights to Bone Drug

publication date: Oct 18, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Eddingpharm has in-licensed greater-China rights to a novel osteoporosis treatment from Ablynx, a Belgium biopharma. The drug candidate, ALX-0141, is an anti-RANKL nanobody that has successfully completed a Phase I double-blind trial. Eddingpharma paid $2.7 million upfront, plus it will make additional milestone payments and pay royalties up to 20%, based on sales. Eddingpharm will also underwrite clinical development of the molecule in greater China. More details....

Stock Symbol: (BR: ABLX)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Alibaba IPO
Event Updates
Greg Scott will be attending and speaking at these events:
 
 
 
Hope to see you there!
 
ChinaBio® Events
More events coming soon...

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors